GlassScriptPhysician profile
Jasmin Bafaiz
NPI 1649869231
$4,300.56
in general payments reported to CMS, 2019-2025
19 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $509 · 2022: $861 · 2023: $812 · 2024: $977 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,928 · Travel and Lodging: $2.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.82 |
| Travel and Lodging | $2.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $869.63 | 2022-2025 | |
| Incyte Corporation | $484.23 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $416.02 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $381.41 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Genzyme Corporation | $315.34 | 2021-2025 | |
| Ucb, INC. | $293.70 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $275.73 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $266.90 | 2024 | Zoryve |
| Biofrontera INC. | $198.42 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $186.31 | 2025 | Nemluvio |
| Leo Pharma INC. | $149.99 | 2022-2023 | Adbry |
| Astrazeneca Pharmaceuticals LP | $118.39 | 2023 | Andexxa |
| Amgen INC. | $83.88 | 2021-2022 | |
| Janssen Biotech, INC. | $62.19 | 2022-2023 | Tremfya |
| Pfizer INC. | $56.80 | 2022-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $49.74 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $47.57 | 2024 | Clear+Brilliant |
| Novartis Pharmaceuticals Corporation | $22.92 | 2022 | |
| Organon LLC | $21.39 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmin Bafaiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.